Suppr超能文献

基于验证的插入突变(VBIM):一种强大的正向遗传筛选策略。

Validation-Based Insertional Mutagenesis (VBIM), A Powerful Forward Genetic Screening Strategy.

机构信息

Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.

Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio.

出版信息

Curr Protoc. 2022 Mar;2(3):e394. doi: 10.1002/cpz1.394.

Abstract

Forward genetics begins with a biological phenotype and attempts to identify genetic changes that influence that phenotype. These changes can be induced in a selected group of genes, for instance, by using libraries of cDNAs, shRNAs, CRISPR guide RNAs, or genetic suppressor elements (GSEs), or randomly throughout the genome using chemical or insertional mutagens, with each approach creating distinct genetic changes. The Validation-Based Insertional Mutagenesis (VBIM) strategy utilizes modified lentiviruses as insertional mutagens, placing strong promoters throughout the genome. Generating libraries with millions of cells carrying one or a few VBIM promoter insertions is straightforward, allowing selection of cells in which overexpression of VBIM-driven RNAs or proteins promote the phenotype of interest. VBIM-driven RNAs may encode full-length proteins, truncated proteins (which may have wild-type, constitutive, or dominant-negative activity), or antisense RNAs that can disrupt gene expression. The diversity in VBIM-driven changes allows for the identification of both gain-of-function and loss-of-function mutations in a single screen. Additionally, VBIM can target any genomic locus, regardless of whether it is expressed in the cells under study or known to have a biological function, allowing for true whole-genome screens without the complication and cost of constructing, maintaining, and delivering a comprehensive library. Here, we review the VBIM strategy and discuss examples in which VBIM has been successfully used in diverse screens to identify novel genes or novel functions for known genes. In addition, we discuss considerations for transitioning the VBIM strategy to in vivo screens. We hope that other laboratories will be encouraged to use the VBIM strategy to identify genes that influence their phenotypes of interest. © 2022 Wiley Periodicals LLC.

摘要

正向遗传学从生物表型开始,试图鉴定影响该表型的遗传变化。这些变化可以在选定的一组基因中诱导,例如,使用 cDNA、shRNA、CRISPR 向导 RNA 或遗传抑制元件 (GSE) 的文库,或使用化学诱变剂或插入诱变剂随机地在整个基因组中进行,每种方法都会产生不同的遗传变化。基于验证的插入诱变 (VBIM) 策略利用改良的慢病毒作为插入诱变剂,在整个基因组中放置强启动子。通过这种方法,生成携带一个或几个 VBIM 启动子插入的数百万个细胞文库是很简单的,可以选择 VBIM 驱动的 RNA 或蛋白质过表达促进感兴趣表型的细胞。VBIM 驱动的 RNA 可以编码全长蛋白、截断蛋白(可能具有野生型、组成型或显性负性活性)或反义 RNA,可破坏基因表达。VBIM 驱动的变化的多样性允许在单个筛选中鉴定功能获得和功能丧失突变。此外,VBIM 可以靶向任何基因组位点,无论其是否在研究中的细胞中表达或已知具有生物学功能,允许进行真正的全基因组筛选,而无需构建、维护和提供综合文库的复杂性和成本。在这里,我们回顾了 VBIM 策略,并讨论了 VBIM 在各种筛选中成功用于鉴定新基因或已知基因的新功能的示例。此外,我们还讨论了将 VBIM 策略转化为体内筛选的注意事项。我们希望其他实验室将受到鼓励,使用 VBIM 策略来鉴定影响其感兴趣表型的基因。© 2022 Wiley Periodicals LLC.

相似文献

6
Cancer gene discovery: exploiting insertional mutagenesis.癌症基因的发现:利用插入诱变。
Mol Cancer Res. 2013 Oct;11(10):1141-58. doi: 10.1158/1541-7786.MCR-13-0244. Epub 2013 Aug 8.

本文引用的文献

2
Breast Cancer, Mutations, and Overcoming Drug Resistance.乳腺癌、突变与克服耐药性
N Engl J Med. 2021 Sep 23;385(13):1241-1243. doi: 10.1056/NEJMcibr2110552.
3
Loss of ZIP facilitates JAK2-STAT3 activation in tamoxifen-resistant breast cancer.ZIP 的缺失促进了他莫昔芬耐药乳腺癌中 JAK2-STAT3 的激活。
Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):15047-15054. doi: 10.1073/pnas.1910278117. Epub 2020 Jun 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验